

## **2014 – 2015 Provider Tips for Optimizing HEDIS® Results**

HEDIS MEASURE	REQUIRED DOCUMENTATION	PROVIDER SPECIALITY	BILLING TIPS
Childhood Immunizations	Combo 2	No provider requirements specified.	
	4 doses – DTaP/DT     3 doses – IPV		Codes for Immunizations:
Immunizations must occur	• 1 doses – MMR		DTaP Hep B Hib IPV MMR PCV VZV
on or before child's 2nd birthday	3 doses – Hib     3 doses – Hep B		CPT
bii tiiday	• 1 dose – VZV		90698 90723 90645- 90698 90707 90669 90710 90700 90740 90648 90713 90710 90670 90716
	Document all seropositives and illness history of chicken pox, measles,		90721 90744 90698 90723 <u>HCPCS</u>
	mumps, and rubella. Document the first Hep B vaccine given at the		90723 90747 90721 G0009 90748 90748
	hospital or at birth when applicable, or if unavailable, name of hospital		HCPCS
	where child was born.		G0010
			History of Disease Diagnosis Codes:
			Chicken Measles Mumps Rubella
			Pox
			<u>ICD-9</u>
			053
			*In order to be reimbursed for the Immunization the Vaccine code must be billed along with the following Administration Code
l	Complete Immunizations:	No provider requirements specified.	90460, 90471-90474
Immunizations for Adolescents	1 dose – Meningococcal Conjugate or Meningococcal	No provider requirements specified.	CPT Codes for Immunizations:
Adolescents	Polysaccharide Vaccine on or between the member's 11th and 13th		
Members age 13 years	birthdays  • 1 dose – Tetanus, Diphtheria Toxoids Vaccine (Td) on or between		Diphtheria         Meningococcal         Td         Tdap         Tetanus           90719         90733         90714         90715         90703
during the measurement	the member's 10th and 13th birthdays		90734 90718
year	Document a note indicating the name of the specific antigen and the		
,	date of the immunization OR document a certificate of immunization		*In order to be reimbursed for the Immunization the Vaccine code must be billed along with the following Administration Code.
	prepared by an authorized health care provider or agency, including		90460, 90471-90474
Lead Screening	the specific dates and types of immunizations administered.  For all children turning 2 years old in the measurement year, a lead	No provider requirements specified.	<u>CPT</u>
Members age turning age 2	blood test must be completed before their second birthday.		83655
during the measurement			
year			
Well Care Visits	Ages 0-15 months: 6 visits in the first 15 months of life	Primary Care Physician (PCP): A	
Members age 0-21 years	Ages 18-30 months: 3 visits (one every 6 months) Ages 3-6 years: 1 visit annually	physician or non-physician (e.g. nurse practitioner) who offers	CPT ICD-9 99381 or 99391 (younger than 1 year) V20.3 Newborn check under 8 days old
	Ages 7-11 years: 1 visit annually	primary care medical services.	99382 or 99392 (age 1-4 years) V20.3 Newborn check 8 – 28 days old
	Ages 12-21 years: 1 visit annually	General or family practice	99383 or 99393 (age 5-11 years) V20.2 Routine infant or child health check
	All three components of a Well Child Visit must be included:	<ul><li>physician</li><li>General internal medicine</li></ul>	99384 or 99394 (age 12-17 years) V70.0 Routine general medical examination 99385 or 99395 (18 years and older)
	Health and Development History (physical and mental)	physician	
	Physical Examination     Health Education/Anticipatory Guidance	General pediatrician     Obstatrician /gryposologist	The codes do not have to be primary codes.
	Realth Education/Anticipatory Guidance	Obstetrician/gynecologist     (OB/GYN)	Well visits can be done in conjunction with sick visits as long as they are billed with the appropriate modifier.
		Certified nurse midwife, nurse	Well visits can be performed anytime in the measurement/calendar year.
		practitioner, and physician assistant under the direction of an	
		OB/GYN certified provider	
Weight Assessment &	Ages 3 – 15 years on the date of service, documentation of:	PCP     OB/GYN	DAAL Counceling
Counseling for Nutrition &	BMI percentile or BMI percentile plotted on age-growth chart	• OB/GYN	BMI Counseling  Percentile Value (ages 16-17) Nutrition Physical Activity
Physical Activity for	(A BMI value is not acceptable for this age range)  • Counseling for nutrition		<u>ICD-9</u> <u>ICD-9</u> <u>ICD-9</u>
Children/Adolescents	Counseling for hysical activity		V85.51 V85.0 – V85.45 V65.3 V65.41 V85.52
(WCC) Members age 3 –17 years	Ages 16 –17 years on the date of service, documentation of:		V85.53 <u>CPT</u>
years	BMI value expressed as kg/m² is acceptable		V85.54 97802-97804
	Counseling for nutrition     Counseling for physical activity		Exclusions: Members with diagnosis of pregnancy during the measurement year or year prior.
Use of Appropriate	Members 5– 64 years of age during the measurement year who were	No provider requirements specified.	Exclusions. Members with alagnosis of pregnancy during the measurement year of year prior.
Medications for People	identified as having persistent asthma who were appropriately		Controller Medications: Preferred Asthma Therapy Medications:
With Asthma	prescribed medication during the measurement year.		Description Prescriptions
Members age 5–64 years	1		
	Four age stratifications and a total rate are reported:		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline
	• 5-11 years		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone,
	<ul><li>5-11 years</li><li>12-18 years</li></ul>		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone
	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> </ul>		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone,
	<ul><li>5-11 years</li><li>12-18 years</li><li>19-50 years</li></ul>		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol
	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> </ul>		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton
	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> </ul>		Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during
	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul>	Prenatal Care Provider	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone beukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute
Prenatal Postpartum	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care	Prenatal Care Provider  • OB/GYN	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during
Prenatal Postpartum Care	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of</li> </ul>	OB/GYN     Midwife or nurse practitioner	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab linhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits  ICD-9 CPT ICD-9 CPT HCPCS UB
<b>Care</b> Women who had a	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> </ul>	OB/GYN	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits  ICD-9 CPT ICD-9 CPT HCPCS UB V22-V23 99201-99205 V24.1 57170 G0123 0923
Care	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN  Primary Care Provider	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits    CD-9
<b>Care</b> Women who had a	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits  ICD-9 CPT HCPCS UB V22-V23 99201-99205 V24.1 57170 G0123 0923 V28 99211-99215 V24.2 58300 G0124 99241-99245 V25.11 59430 G0141 99500 V25.12 88141–88143 G0143
Care  Women who had a live delivery between	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> </ul> Postpartum Care <ul> <li>A visit that occurs on or between 21–56 days after delivery.</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN  Primary Care Provider	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits    ICD-9
Care  Women who had a live delivery between November 6th of the year prior to the measurement year	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> </ul> Postpartum Care <ul> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline Antibody inhibitor omalizumab Inhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits  ICD-9 CPT HCPCS UB V22-V23 99201-99205 V24.1 57170 G0123 0923 V28 99211-99215 V24.2 58300 G0124 99241-99245 V25.11 59430 G0141 99500 V25.12 88141–88143 G0143
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.    Prenatal Visits
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab linhaled corticosteroids beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.    Prenatal Visits   Postpartum Visits
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Leukotriene modifiers Mast cell stabilizers Methylxanthines  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits  Postpartum Visits    CD-9
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Leukotriene modifiers Mast cell stabilizers Methylxanthines  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits  Postpartum Visits  ICD-9 V22-V23 99201-99205 V24.1 57170 G0123 0923 V28 99211-99215 V24.2 58300 G0124 99241-99245 V25.11 59430 G0141 99500 V25.12 88141-88143 G0143 V25.13 88147 G0144 V72.31 88148 G0145 V72.32 88150 G0147 V76.2 88150 G0147 V76.2 88150 G0148 88164-88167 P3000 88174 P3001 88175 Q0091 99501
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented</li> </ul>	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Leukotriene modifiers Mast cell stabilizers Methylxanthines  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits  Postpartum Visits    CD-9
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Inhal
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Leukotriene modifiers Mast cell stabilizers Methylxanthines  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits  Postpartum Visits    CD-9
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor Inhaled corticosteroids Inhaled steroid Inhal
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone budesonide del stabilizers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn dyphylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn dyphylline, dyphylline, theophylline, theophylline, theophylline dyphylline, dyphylline, theophylline, dyphylline, dyp
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline cespiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits    CD-9 CPT   CD-9 CPT   HCPCS UB
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening  Women age 16 –24 years	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant	Antiasthmatic Antibody inhibitor omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone budesonide del stabilizers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol montelukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn dyphylline, dyphylline, theophylline budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zileuton cromolyn dyphylline, dyphylline, theophylline, theophylline, theophylline dyphylline, dyphylline, theophylline, dyphylline, dyp
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening Women age 16 –24 years	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the measurement year.	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant      No provider requirements specified.	Antibody inhibitor Inhaled corticosteroids Inhaled steroid triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton Methylxanthines cromolyn, nedocromil aminophylline, dyphylline, theophylline  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits Postpartum Visits  ICD-9 CPT ICD-9 CPT HCPCS UB 9921-99215 V24.1 57170 G0123 0923 V28 99211-99215 V24.2 58300 G0124 99241-99245 V25.11 59430 G0141 99500 V25.12 88141-88143 G0144 V72.31 88148 G0145 V25.33 88147 G0144 V72.31 88148 G0145 V72.32 88150 G0147 V76.2 88152-88154 G0148 88164-88167 P3000 88174 P3001 88175 Q0091 99501  CPT 87110 87270 87320 873920 87490-87492 87810  Exclusions: Members who had a pregnancy test during the measurement year followed within seven days (inclusive) by either a prescription for isotretinoin (Accutane) or xray. Pregnancy test alone does not apply. This measure is Medical Record Review Only.
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening  Women age 16 –24 years	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the measurement year. Documentation of the most recent BP reading during the measurement year after the diagnosis of hypertension was made.	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant      No provider requirements specified.	Antiasthmatic dyphylline-guaifenesin, guaifenesin-theophylline omalizumab beclomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol montelukast, zafirlukast, zileuton cromolyn, nedocromil aminophylline, dyphylline, theophylline exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/vapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.    Prenatal Visits
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening Women age 16 –24 years  Controlling High BP	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the measurement year. Documentation of the most recent BP reading during the	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant      No provider requirements specified.	Antibody inhibitor Inhaled corticosteroids Inhaled corticosteroids Inhaled corticosteroids Inhaled corticosteroids Inhaled steroid Leukotriene modifiers Mast cell stabilizers Mothylanthines  Exclusions: Emphysema, COPD, Chronic respiratory conditions due to fumes/wapors, cystic fibrosis, acute respiratory failure, and members who have had no asthma controller medications dispensed during measurement year.  Prenatal Visits  Postpartum Visits  ICD-9 V22-V23 99201-99205 V24.1 57170 G0123 0923 V28 99211-99215 V24.2 58300 G0124 99241-99245 V25.11 59430 G0141 99500 V25.12 88141-88143 G0143 V27.31 88148 G0145 V72.31 88148 G0145 V72.32 88150 G0147 V76.2 88152-88154 G0148 88164-88167 P3000 88174 P3001 88175 Q0091 99501  CPT 87110 87270 87320 87490-87492 87810  Exclusions: Members who had a pregnancy test during the measurement year followed within seven days (inclusive) by either a prescription for isotretinoin (Accutane) or xray. Pregnancy test alone does not apply.  This measure is Medical Record Review Only.  Diagnosis and documented BP must come from the same medical practitioner.
Care  Women who had a live delivery between November 6th of the year prior to the measurement year and November 5th of the measurement year.  Chlamydia Screening Women age 16 –24 years  Controlling High BP	<ul> <li>5-11 years</li> <li>12-18 years</li> <li>19-50 years</li> <li>51-64 years</li> <li>Total</li> </ul> Prenatal Care <ul> <li>A prenatal visit within the 1st trimester or within 42 days of enrollment</li> <li>Postpartum Care</li> <li>A visit that occurs on or between 21–56 days after delivery.</li> <li>Components of a postpartum exam visit note:</li> <li>Pelvic exam, OR</li> <li>Weight, BP, breast and abdominal evaluation, and breast feeding status, OR</li> <li>PP check, PP Care, six-week check notation, or pre-printed "Postpartum Care" form in which information was documented during the visit</li> </ul> Documentation of at least one chlamydia test during the measurement year. Documentation of the most recent BP reading during the measurement year after the diagnosis of hypertension was made. Documentation of diagnosis with hypertension (HTN) and whose BP	OB/GYN     Midwife or nurse practitioner under the direction of an OB/GYN      Primary Care Provider     Family practitioner or other PCP     Nurse practitioner or physician assistant      No provider requirements specified.	Antibody inhibitor omalizumab becomethasone, budesonide, ciclesonide, flunisolide, mometasone, linhaled corticosteroids becomethasone, budesonide, ciclesonide, flunisolide, mometasone, triamcinolone Leukotriene modifiers budesonide-formoterol, fluticasone-salmeterol, mometasone-formoterol Mast cell stabilizers montelukast, zafirlukast, zileuton montelukast, zafirlukast, zafirlukast, zafirlukast, zileuton montelukast, zafirlukast, zi

HEDIS Tip Sheet – Key					
Children	Both	Adults			
Well Care Visits	Controlling High Blood Pressure	Adult BMI Assessment			
Childhood Immunizations	Diabetic Eye Exam	Breast Cancer Screening			
Immunizations for Adolescents	Diabetic HbA1c Testing	Cervical Cancer Screening			
Lead Screening	Diabetic Nephropathy Screening	Colorectal Cancer Screening			
Weight Assessment & Counseling for Nutrition &	Diabetic Blood Pressure Control				
Physical Activity	7-Day Follow-up After Hospitalization				
	Appropriate Asthma Medication Use				
	Prenatal and Postpartum Care				

 ${\it Please\ distribute\ to\ billing\ and\ office\ personnel\ as\ appropriate}.$ 

Contact your Clinical Practice Consultant with any questions.

The codes contained in this HEDIS guide are examples of codes typically billed for the various types of services and may change from year to year. Submitting claims using these codes helps improve reporting of quality measures performed. Please keep in mind, billing these codes does not guarantee payment.

Diabetic Eye Exam  Members age 18–75 years  with diabetes	Optometrist/ophthalmologist exam every two years for patients without retinopathy and every year with diabetic retinopathy. At a minimum, documentation in the medical record must include one of the following:  • A letter prepared by an optometrist, ophthalmologist, PCP or other health care professional indicating that an ophthalmoscopic exam was completed, the date when the procedure was performed, and the results.  • A chart or photograph of retinal abnormalities indicating the date when the fundus photography was performed and evidence that an eye care professional reviewed the results. Alternatively, results may be read by a qualified reading center that operates under the direction of a medical director who is a retinal specialist.  • Documentation of a negative retinal or dilated exam by an eye care professional in the year prior to the measurement year, where results indicate retinopathy was not present	Ophthalmologist     Optometrist	CPT: 67028, 67030, 67031, 67036, 67039–67043, 67101, 67105, 67107, 67108, 67110, 67112, 67113, 67121, 67141, 67145, 67208, 67210, 67218, 67220, 67221, 67227, 67228, 92002, 92004, 92014, 92014, 92018, 92019, 92134, 92225–92228, 92230, 92235, 92240, 92250, 92260, 99203–99205, 99213–99215, 99242–99245  HCPCS: S0620, S0621, S3000  Exclusions: Members that are not diabetic per current PCP documentation, OR members with a diagnosis of polycystic ovaries, gestational diabetes, or steroid induced diabetes.  Send exclusion documentation to JHHC QI via confidential fax to: 410-762-5941.
Diabetic HbA1c Testing and Control Members age 18–75 years with diabetes	At a minimum, documentation in the medical record must include a note indicating the date when the HbA1c test was performed and the result. To be considered controlled, the most recent HbA1c must be <8.0%.	No provider requirements specified.	HbA1c Test  CPT B3036 B3036 B3037 B3037 B4549-2 B3036 B3037
Diabetic BP Control Members age 18–75 years with diabetes	Documentation in the medical record must include the most recent BP taken during the measurement year. Adequately controlled BP must be <140/90 during the measurement year.	No provider requirements specified.	The most recent blood pressure must be documented in the medical record and <140/90 to be considered controlled.  Exclusions: Members that are not diabetic per current PCP documentation, OR members with a diagnosis of polycystic ovaries, gestational diabetes, or steroid induced diabetes.
Diabetic Nephropathy Monitoring Members age 18–75 years with diabetes	Evidence of one of the following, per year:  Nephropathy screening test Treatment for nephropathy or ACE/ARB therapy Evidence of stage 4 chronic kidney disease Evidence of ESRD Evidence of a kidney transplant A positive urine macroalbumin test	No provider requirements specified.	Nephropathy Positive Urine Nephropathy Treatment Screening Test Macroalbumin  CPT CPT CPT ICD-9 82042 3062F 3066F Codes available upon request 82043 4010F 82044 84156  Exclusions: Members that are not diabetic per current PCP documentation, OR members with a diagnosis of polycystic ovaries, gestational diabetes, or steroid induced diabetes.
7-Day Follow-up After Hospitalization Members age 6 and older	Documentation of an outpatient visit with a mental health practitioner within 7 days after discharge with a selective mental health disorder.  Only facility claim identifies a discharge.  Mental Health Diagnosis:  ICD-9 295–299, 300.3, 300.4, 301, 308, 309, 311–314	Mental Health Practitioner: Psychiatrist Psychologist Psychiatric nurse practitioner Masters prepared social worker Clinical nurse specialist Certified marital and family therapist (MFT) Professional counselor (PCC, PCC-S)	CPT: 98960-98962, 99078, 99201-99205, 99211-99215,99217-99220, 99241-99245, 9341-99345, 99347-99350, 99383-99387, 99393-99397, 99401-99404, 99411, 99412, 99510  HCPCS: G0155, G0176, G0177, G0409-G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485;
Adult BMI Assessment Members age 18–74 years	Documentation in the medical record must indicate the weight and BMI value dated during the measurement year or year prior to the measurement year.  Members younger than 19 years:  BMI percentile documented as a value (e.g., 85th percentile)  BMI percentile plotted on an age-growth chart	No provider requirements specified.	ICD-9: V85.0-V85.5   CPT: 99201-99205, 992211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99420, 99429, 99455, 99456   Exclusions: Members with diagnosis of pregnancy during the measurement year or year prior.
Breast Cancer Screening Women age 52–74 years	One or more mammograms any time on or between October 1st, two years prior to the measurement year, and December 31st of the measurement year.  Obtain a copy of mammogram results or record date of test and result.  This measure evaluates primary screening. Do not count biopsies, breast ultrasounds, or MRIs because they are not appropriate methods for primary breast cancer screening.	No provider requirements specified.	Coding to Identify Mammogram:   CPT
Cervical Cancer Screening Women age 24–64 years  (two-year look-back includes Paps given at age 21)	The percentage of women 21–64 years of age who were screened for cervical cancer using either of the following criteria:  • ages 21–64 who had cervical cytology performed every 3 years  • ages 30 – 64 who had cervical cytology/human papillomavirus (HPV) co-testing performed every 5 years  The following does not qualify:  • Lab results that indicate inadequate sample or no cervical cells  Referral to OB/GY N alone does not meet the measure. Biopsies are considered diagnostic and do not meet the measure.	No provider requirements specified.	Cervical Cytology  CPT
Colorectal Cancer Screening Members age 51-75 years	One or more screenings for colorectal cancer.  Appropriate screenings are defined by one of the following:  • FOBT during the measurement year  • Flexible sigmoidoscopy during the measurement year or the four years prior to the measurement year  • Colonoscopy during the measurement year or the nine years prior to the measurement year	No provider requirements specified.	Colonoscopy   Flexible Sigmoidoscopy   FOBT

The CareSource *Clinical Practice Registry* and *Member Profile* are available to providers to look up services and tests needed for members.

To access the CareSource *Clinical Practice Registry* and *Member Profile*, please visit <u>caresource.com</u>.

- The *Clinical Practice Registry* can be found by clicking Providers > Member Care > Clinical Guidelines
- *Member Profiles* can be found by logging on the Provider Portal

## $How\ to\ improve\ your\ HEDIS\ score$

- You will receive the highest scores if you document all services and procedures on a claim as this  $\,$  ensures you will receive credit.
- Using codes as outlined on this document may also decrease the number of chart reviews required during HEDIS data collection.
- Members may be incorrectly identified as diabetic through ER claims. If this is the case with your member, send in a copy of the member's problem list or progress notes to validate "not a diabetic."